188 results on '"Yap, Jeffrey T."'
Search Results
2. Abstract 355: Examination of systemic myokine concentrations with risk of cachexia in non-metastatic colorectal cancer patients - Results from the ColoCare Study
3. Data from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
4. Supplementary Figure 7 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
5. Supplementary Figure Legends from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
6. Supplementary Figure 1 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
7. Supplementary Figure 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
8. Supplementary Table 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
9. Supplementary Table 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
10. Supplementary Figure 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
11. Supplementary Methods from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
12. Supplementary Table 1 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
13. Supplementary Figure 6 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
14. Supplementary Table 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
15. Supplementary Figure 5 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
16. Supplementary Figure 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
17. Prospective Pilot Study of 18F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas
18. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
19. MRI of Hypoxia in Primary Central Nervous System Tumors: Part II
20. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma
21. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
22. Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
23. Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans
24. Abstract 3221: Differences in body composition among rectal cancer patients with neo-adjuvant treatment-related toxicity: Results from the ColoCare Study
25. CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer: Performance Characteristics of an Emerging Clinical Tool
26. Abstract A45: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
27. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study
28. Cold‐Activated Brown Adipose Tissue is Associated with Less Cardiometabolic Dysfunction in Young Adults with Obesity
29. Image reconstruction for dynamic PET based on low-order approximation and restoration of the sinogram
30. Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate
31. Classification of Dynamic PET Images Using a Priori Kinetic Factors
32. Contributors
33. Sinogram Recovery of Dynamic PET Using Principal Component Analysis and Projections onto Convex Sets
34. Generation of Parametric Images Using Factor Analysis of Dynamic PET
35. Contributors
36. Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer
37. Lipopolysaccharide endotoxemia induces amyloid-β and p-tau formation in the rat brain
38. Abstract 2183: Protective autophagy elicited by RAF®MEK®ERK inhibition suggests a treatment strategy for pancreatic cancer
39. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
40. The Influential Role of BCL2 Family Members in Synovial Sarcomagenesis
41. [IC-P-007]: HOW AMYLOID PET CHANGES COGNITIVE CARE: A BROADER VIEW
42. [P2-396]: HOW AMYLOID PET CHANGES COGNITIVE CARE: A BROADER VIEW
43. Method for detecting voxelwise changes in fluorodeoxyglucose-positron emission tomography brain images via background adjustment in cancer clinical trials
44. Association of genomically unstable Ewing sarcoma tumors with HOTAIR overexpression and clinical outcome.
45. Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology
46. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
47. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma
48. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)
49. Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials
50. HOW AMYLOID PET CHANGES COGNITIVE CARE: A BROADER VIEW
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.